An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma

References

• Huang JJ, Hsieh JJ. The therapeutic landscape of renal cell carcinoma: from the dark age to the golden age. Semin Nephrol. 2020;40(1):28–41.
   PubMed Web of Science ®Google Scholar
• Rosellini M, Marchetti A, Tassinari E, et al. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Rev Precis Med Drug Dev. 2022;7(1):131–149. DOI:10.1080/23808993.2022.2156786
   Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290. DOI:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. DOI:10.1136/esmoopen-2020-001079
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. DOI:10.1056/NEJMoa1816714.
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. DOI:10.1056/NEJMoa2035716.
   PubMed Web of Science ®Google Scholar
• Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2020 Dec;21(12): e553]. Lancet Oncol. 2020;21(12):1563–1573. DOI:10.1016/S1470-2045(20)30436-8
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228–238. DOI:10.1016/S1470-2045(23)00049-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. DOI:10.1056/NEJMoa2026982.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888–898. DOI:10.1016/S1470-2045(22)00290-X
   PubMed Web of Science ®Google Scholar
• Powles T, Albiges L, Bex A, et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511–1519. DOI:10.1016/j.annonc.2021.09.014
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82(4):399–410.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(1):71–90. DOI:10.6004/jnccn.2022.0001
   PubMedGoogle Scholar
• Massari F, Mollica V, Rizzo A, et al. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(10):1329–1338. DOI:10.1080/14740338.2020.1811226
   PubMed Web of Science ®Google Scholar
• Rizzo A, Nuvola G, Palmiotti G, et al. Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy. 2023;15(2):117–126. DOI:10.2217/imt-2022-0023
   PubMedGoogle Scholar
• Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128(11):2085–2097. DOI:10.1002/cncr.34180
   PubMed Web of Science ®Google Scholar
• Joly F, Vardy J, Pintilie M, et al. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. 2007;18(12):1935–1942.
   PubMed Web of Science ®Google Scholar
• Malone E, Barua R, Meti N, et al. Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: a systematic review. Cancer Med. 2021;10(15):5031–5040. DOI:10.1002/cam4.4086
   PubMed Web of Science ®Google Scholar
• Rizzo A, Mollica V, Dall’olio FG, et al. Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncol. 2021;17(20):2671–2681. DOI:10.2217/fon-2021-0069
   PubMed Web of Science ®Google Scholar
• Cella D, Grünwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019;20(2):297–310. DOI:10.1016/S1470-2045(18)30778-2.
   PubMed Web of Science ®Google Scholar
• Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022;23(6):768–780. DOI:10.1016/S1470-2045(22)00212-1.
   PubMed Web of Science ®Google Scholar
• Cella D, Motzer RJ, Suarez C, et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(2):292–303. DOI:10.1016/S1470-2045(21)00693-8.
   PubMed Web of Science ®Google Scholar
• Bedke J, Rini BI, Plimack ER, et al. Health-related Quality of Life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. Eur Urol. 2022;82(4):427–439. DOI:10.1016/j.eururo.2022.06.009.
   PubMed Web of Science ®Google Scholar
• Deshpande PR, Rajan S, Sudeepthi BL, et al. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2(4):137–144. DOI:10.4103/2229-3485.86879
   PubMedGoogle Scholar
• Cocks K, King MT, Velikova G, et al. Quality, interpretation and presentation of European organisation for research and treatment of cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;44(13):1793–1798. DOI:10.1016/j.ejca.2008.05.008
   PubMed Web of Science ®Google Scholar
• Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health. 2007;10(4):285–293. DOI:10.1111/j.1524-4733.2007.00183.x
   PubMed Web of Science ®Google Scholar
• Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5(1):70.
   PubMedGoogle Scholar
• Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–109. DOI:10.1016/j.jclinepi.2007.03.012
   PubMed Web of Science ®Google Scholar
• Nolla K, Benjamin DJ, Cella D. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment [published online ahead of print, 2023 Mar 16]. Nat Rev Urol. 2023. DOI:10.1038/s41585-023-00747-w
   PubMed Web of Science ®Google Scholar
• Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya ̄ Indian J Stat. 2010;62:134–148.
   Google Scholar
• Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30(12):1371–1377. DOI:10.1200/JCO.2011.36.4133
   PubMed Web of Science ®Google Scholar
• Kase AM, George DJ, Ramalingam S. Clear cell renal cell carcinoma: from biology to treatment. Cancers (Basel). 2023;15(3):665.
   PubMed Web of Science ®Google Scholar
• Massari F, Rizzo A, Mollica V, et al. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer. 2021;154:120–127.
   PubMed Web of Science ®Google Scholar
• Quhal F, Mori K, Remzi M, et al. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. Curr Opin Urol. 2021;31(4):332–339. DOI:10.1097/MOU.0000000000000889
   PubMed Web of Science ®Google Scholar
• Riaz IB, He H, Ryu AJ, et al. A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma. Eur Urol. 2021;80(6):712–723. DOI:10.1016/j.eururo.2021.03.016
   PubMed Web of Science ®Google Scholar
• Rizzo A, Santoni M, Mollica V, et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021;17(12):1455–1466. DOI:10.1080/17425255.2021.2029405
   PubMed Web of Science ®Google Scholar
• Chen YW, Rini BI. Approaches to first-line therapy for metastatic clear cell renal cell carcinoma. Curr Oncol Rep. 2022;24(6):695–702.
   PubMed Web of Science ®Google Scholar
• Agarwal M, Thareja N, Benjamin M, et al. Tyrosine Kinase Inhibitor-Induced Hypertension. Curr Oncol Rep. 2018;20(8):65. DOI:10.1007/s11912-018-0708-8
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade [published correction appears in Cell. 2022 Feb 3;185(3): 576]. Cell. 2021;184(21):5309–5337. DOI:10.1016/j.cell.2021.09.020
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.
   PubMed Web of Science ®Google Scholar
• Tannir NM, Motzer RJ, Plimack ER, et al. Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214. J Clin Oncol. 2019;37(7_suppl):581. DOI:10.1200/JCO.2019.37.7_suppl.581
   Web of Science ®Google Scholar
• Rosellini M, Marchetti A, Mollica V, et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol. 2023;20(3):133–157. DOI:10.1038/s41585-022-00676-0
   PubMed Web of Science ®Google Scholar
• Remash D, Prince DS, McKenzie C, et al. Immune checkpoint inhibitor-related hepatotoxicity: a review. World J Gastroenterol. 2021;27(32):5376–5391. DOI:10.3748/wjg.v27.i32.5376
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Palazzo A, Procopio G, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol. 2014;77(6):929–938. DOI:10.1111/bcp.12231
   PubMed Web of Science ®Google Scholar
• Saran C, Sundqvist L, Ho H, et al. Novel bile acid-dependent mechanisms of hepatotoxicity associated with tyrosine kinase inhibitors. J Pharmacol Exp Ther. 2022;380(2):114–125. DOI:10.1124/jpet.121.000828
   PubMed Web of Science ®Google Scholar
• Rizzo A, Mollica V, Tateo V, et al. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study [published online ahead of print, 2023 Jan 25]. Cancer Immunol Immunother. 2023. DOI:10.1007/s00262-023-03366-x
   Web of Science ®Google Scholar
• Rini BI, Atkins MB, Plimack ER, et al. Characterization and management of treatment-emergent hepatic toxicity in patients with advanced renal cell carcinoma receiving first-line pembrolizumab plus axitinib. Results from the KEYNOTE-426 trial. Eur Urol Oncol. 2022;5(2):225–234. DOI:10.1016/j.euo.2021.05.007
   PubMed Web of Science ®Google Scholar
• McGregor B, Mortazavi A, Cordes L, et al. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review. Cancer Treat Rev. 2022;103:102333.
   PubMed Web of Science ®Google Scholar
• Aeppli S, Schmaus M, Eisen T, et al. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open. 2021;6(1):100030. DOI:10.1016/j.esmoop.2020.100030
   PubMed Web of Science ®Google Scholar
• Meserve J, Facciorusso A, Holmer AK, et al. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021;53(3):374–382. DOI:10.1111/apt.16217
   PubMed Web of Science ®Google Scholar
• Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154–1161. DOI:10.1093/annonc/mdz110
   PubMed Web of Science ®Google Scholar
• Bimbatti D, Dionese M, Lai E, et al. Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: a real-world, single-centre experience. Front Oncol. 2022;12:960751.
   PubMed Web of Science ®Google Scholar
• Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6(6):865–871. DOI:10.1001/jamaoncol.2020.0726
   PubMed Web of Science ®Google Scholar
• Buckley HL, Collinson FJ, Ainsworth G, et al. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer. 2019;19(1):1102. DOI:10.1186/s12885-019-6273-1
   PubMed Web of Science ®Google Scholar
• Sitlinger A, Zafar SY. Health-related quality of life: the impact on morbidity and mortality. Surg Oncol Clin N Am. 2018;27(4):675–684.
   PubMed Web of Science ®Google Scholar
• Bottomley A, Reijneveld JC, Koller M, et al. Current state of quality of life and patient-reported outcomes research. Eur J Cancer. 2019;121:55–63.
   PubMed Web of Science ®Google Scholar
• Atkinson TM, Wagner JS, Basch E. Trustworthiness of patient-reported outcomes in unblinded cancer clinical trials. JAMA Oncol. 2017;3(6):738–739.
   PubMed Web of Science ®Google Scholar
• Re ZB, Bedke J, Rini BI, et al. Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. Eur Urol. 2022;82(4):427–439. Eur Urol. 82(6):e174-e175 (2022). 10.1016/j.eururo.2022.06.009
   PubMed Web of Science ®Google Scholar
• Faury S, Foucaud J. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: a systematic review on reporting of methods in randomized controlled trials. PLoS ONE. 2020;15(1):e0227344.
   PubMed Web of Science ®Google Scholar
• Hall ET, Singhal S, Dickerson J, et al. Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: opportunities for palliative care-a systematic review. J Pain Symptom Manage. 2019;58(1):137–156.e1. DOI:10.1016/j.jpainsymman.2019.03.015
   PubMed Web of Science ®Google Scholar
• Di Lauro V, Barchiesi G, Martorana F, et al. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. ESMO Open. 2022;7(6):100629. DOI:10.1016/j.esmoop.2022.100629
   PubMed Web of Science ®Google Scholar